If this message does not display properly, please click here to launch your browser.
| Assessing the Impact of Dimebon’s Clinical Trial Failure on the Alzheimer’s Disease Drug Market Based on our Pharmacor advisory service entitled Alzheimer’s Disease, Decision Resources is offering an exclusive analyst call entitled Assessing the Impact of Dimebon’s Clinical Trial Failure on the Alzheimer’s Disease Drug Market. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. The recent failure of Pfizer/Medivation’s Dimebon in the Phase III CONNECTION clinical trial raises questions about the drug’s efficacy in Alzheimer’s disease and about its future market potential. Dimebon, a mitochondrial function modulator that many experts had considered a promising candidate as a symptomatic therapy for Alzheimer’s disease, has been in late stage development for mild-to-moderate and moderate-to-severe Alzheimer’s disease. Dimebon was expected to be a formidable player in the Alzheimer’s disease drug market if it succeeded in Phase III clinical trials. As a result of Dimebon’s failure in the CONNECTION trial, Decision Resources will update its Pharmacor Alzheimer’s Disease advisory service. Following the recent news regarding Dimebon, Decision Resources surveyed U.S. thought leaders and, combined with our own analysis, results from this survey will be discussed in this presentation. This 15-minute analyst call, presented by Analyst Matthew Winton, Ph.D., will answer the following questions:
Dr. Winton will conduct a live Q & A session after the presentation. Registration Assessing the Impact of Dimebon’s Clinical Trial Failure on the Alzheimer’s Disease Drug Market 10 a.m. U.S. Eastern Time, March 18, 2010 IMPORTANT NOTICE: This analyst call will be held at 3 p.m. Central European Time (Paris) on March 18, 2010. To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Matthew J. Winton, Ph.D., is a research analyst in the central nervous system disorders group at Decision Resources. Prior to joining the company, Dr. Winton was a postdoctoral fellow at the University of Pennsylvania School of Medicine, studying the pathogenesis of neurodegenerative disease. He earned a Ph.D. in neurosciences from the University of Montreal, where his research focused on nerve regeneration after spinal cord injury, and holds a B.Sc. in biology and psychology from York University.